266 related articles for article (PubMed ID: 28635153)
1. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Shojaee FSR; Allahyari A; Karimi G
Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
[TBL] [Abstract][Full Text] [Related]
2. Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Hosseini S; Niazi Moghadam MR; Aledavood SA; Karimi G
Phytother Res; 2016 Nov; 30(11):1879-1885. PubMed ID: 27555604
[TBL] [Abstract][Full Text] [Related]
3. Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
Elyasi S; Rasta S; Taghizadeh-Kermani A; Hosseini S
Daru; 2022 Jun; 30(1):117-125. PubMed ID: 35320555
[TBL] [Abstract][Full Text] [Related]
4. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial.
Karbasforooshan H; Hosseini S; Elyasi S; Fani Pakdel A; Karimi G
Phytother Res; 2019 Feb; 33(2):379-386. PubMed ID: 30479044
[TBL] [Abstract][Full Text] [Related]
5. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Kao YS; Lo CH; Tu YK; Hung CH
Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
9. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
[TBL] [Abstract][Full Text] [Related]
10. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL;
J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
17. Topical non-occlusive polymers in hand-foot syndrome.
Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
[TBL] [Abstract][Full Text] [Related]
18. Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial.
Andayani YD; Saleh MI; Sudoyo AW; Ali Z; Legiran L; Partan RU; Yuristo E; Lubis FZ
Acta Med Indones; 2023 Oct; 55(4):396-402. PubMed ID: 38213043
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical
Mohajerani R; Shahi F; Jafariazar Z; Afshar M
Cutan Ocul Toxicol; 2021 Sep; 40(3):257-262. PubMed ID: 34152880
[TBL] [Abstract][Full Text] [Related]
20. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
